REGENXBIO and AbbVie Advance Wet AMD Gene Therapy to Phase III
Phase I/IIa data for a single dose of REGENEXBIO’s gene therapy, RGX-314, shows promise for treating wet age-related macular degeneration.
Phase I/IIa data for a single dose of REGENEXBIO’s gene therapy, RGX-314, shows promise for treating wet age-related macular degeneration.
Segmental allergen challenge in allergic asthmatics reveals a role for monocyte-derived cells in the TH2-dependent inflammatory response.
Drop in 21st Century Cures Act funding will slow BRAIN and All of Us projects
Discovery of potentially complex communication could reveal way to interpret what these marine mammals are saying—but not everyone is convinced
Novel effort comes as study finds key receptor for avian flu virus in udders
Gas combustion in U.S. stoves increases long-term NO2 exposure 4.0 ppbv on average, causing racial and socioeconomic disparities.
CCIO Martin Farrier used to believe AI would “enhance” us. Lately, he’s been having some serious doubts.
A small brain sample was sliced into 5,000 pieces, and machine learning helped stitch it back together.
Inspired by carnival motorbike attractions, the technique could simulate Earth-like gravity on the Moon
Bronchoconstriction causes epithelial cell extrusion that promotes airway inflammation
In the journal Nature Biotechnology, scientists at Ludwig Cancer Research reported the development of an AI model to identify the most effective immune cells for…